-
Je něco špatně v tomto záznamu ?
Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs
I. Truxova, K. Pokorna, K. Kloudova, S. Partlova, R. Spisek, J. Fucikova,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT12402
MZ0
CEP - Centrální evidence projektů
- MeSH
- antigen prezentující buňky účinky léků imunologie metabolismus MeSH
- antigenní specifita receptorů T-buněk imunologie MeSH
- buněčná diferenciace účinky léků imunologie MeSH
- buněčné kultury * MeSH
- časové faktory MeSH
- cytokiny biosyntéza MeSH
- dendritické buňky cytologie účinky léků imunologie metabolismus MeSH
- fagocytóza imunologie MeSH
- fenotyp MeSH
- imunofenotypizace MeSH
- imunoterapie MeSH
- lidé MeSH
- nádory imunologie metabolismus terapie MeSH
- poly I-C imunologie farmakologie MeSH
- protinádorové vakcíny imunologie MeSH
- T-lymfocyty - podskupiny imunologie metabolismus MeSH
- viabilita buněk MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Dendritic cells (DCs) are professional antigen-presenting cells that are capable of inducing immune responses. DC-based vaccines are normally generated using a standard 5- to 7-day protocol. To shorten the DC-based vaccine production for use in cancer immunotherapy, we have developed a fast DC protocol by comparing standard DCs (Day 5 DCs) and fast DCs (Day 3 DCs). METHODS: We tested the generation of Day 5 versus Day 3 DCs using CellGro media and subsequent activation by two activation stimuli: Poly (I:C) and LPS. We evaluated DC morphology, viability, phagocyte activity, cytokine production and ability to stimulate antigen-specific T cells. RESULTS: Day 5 and Day 3 DCs exhibited similar phagocytic capacity. Poly (I:C)-activated Day 5 DCs expressed higher levels of the costimulatory and surface molecules CD80, CD86 and HLA-DR compared to Poly (I:C)-activated Day 3 DCs. Nevertheless, LPS-activated Day 5 and Day 3 DCs were phenotypically similar. Cytokine production was generally stronger when LPS was used as the maturation stimulus, and there were no significant differences between Day 5 and Day 3 DCs. Importantly, Day 5 and Day 3 DCs were able to generate comparable numbers of antigen-specific CD8(+) T cells. The number of Tregs induced by Day 5 and Day 3 DCs was also comparable. CONCLUSION: We identified monocyte-derived DCs generated in CellGro for 3 days and activated using Poly (I:C) similarly potent in most functional aspects as DCs produced by the standard 5 day protocol. These results provide the rationale for the evaluation of faster protocols for DC generation in clinical trials.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014403
- 003
- CZ-PrNML
- 005
- 20191015112443.0
- 007
- ta
- 008
- 150420s2014 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.imlet.2014.03.010 $2 doi
- 035 __
- $a (PubMed)24726860
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Truxová, Iva $u Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic; Sotio, Prague, Czech Republic. $7 xx0238532
- 245 10
- $a Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs / $c I. Truxova, K. Pokorna, K. Kloudova, S. Partlova, R. Spisek, J. Fucikova,
- 520 9_
- $a BACKGROUND: Dendritic cells (DCs) are professional antigen-presenting cells that are capable of inducing immune responses. DC-based vaccines are normally generated using a standard 5- to 7-day protocol. To shorten the DC-based vaccine production for use in cancer immunotherapy, we have developed a fast DC protocol by comparing standard DCs (Day 5 DCs) and fast DCs (Day 3 DCs). METHODS: We tested the generation of Day 5 versus Day 3 DCs using CellGro media and subsequent activation by two activation stimuli: Poly (I:C) and LPS. We evaluated DC morphology, viability, phagocyte activity, cytokine production and ability to stimulate antigen-specific T cells. RESULTS: Day 5 and Day 3 DCs exhibited similar phagocytic capacity. Poly (I:C)-activated Day 5 DCs expressed higher levels of the costimulatory and surface molecules CD80, CD86 and HLA-DR compared to Poly (I:C)-activated Day 3 DCs. Nevertheless, LPS-activated Day 5 and Day 3 DCs were phenotypically similar. Cytokine production was generally stronger when LPS was used as the maturation stimulus, and there were no significant differences between Day 5 and Day 3 DCs. Importantly, Day 5 and Day 3 DCs were able to generate comparable numbers of antigen-specific CD8(+) T cells. The number of Tregs induced by Day 5 and Day 3 DCs was also comparable. CONCLUSION: We identified monocyte-derived DCs generated in CellGro for 3 days and activated using Poly (I:C) similarly potent in most functional aspects as DCs produced by the standard 5 day protocol. These results provide the rationale for the evaluation of faster protocols for DC generation in clinical trials.
- 650 _2
- $a antigen prezentující buňky $x účinky léků $x imunologie $x metabolismus $7 D000938
- 650 _2
- $a protinádorové vakcíny $x imunologie $7 D019496
- 650 12
- $a buněčné kultury $7 D018929
- 650 _2
- $a buněčná diferenciace $x účinky léků $x imunologie $7 D002454
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a cytokiny $x biosyntéza $7 D016207
- 650 _2
- $a dendritické buňky $x cytologie $x účinky léků $x imunologie $x metabolismus $7 D003713
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunofenotypizace $7 D016130
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a nádory $x imunologie $x metabolismus $x terapie $7 D009369
- 650 _2
- $a fagocytóza $x imunologie $7 D010587
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a poly I-C $x imunologie $x farmakologie $7 D011070
- 650 _2
- $a antigenní specifita receptorů T-buněk $x imunologie $7 D037182
- 650 _2
- $a T-lymfocyty - podskupiny $x imunologie $x metabolismus $7 D016176
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pokorná, Kateřina $u Sotio, Prague, Czech Republic. $7 xx0140490
- 700 1_
- $a Kloudová, Kamila $u Sotio, Prague, Czech Republic. $7 xx0240740
- 700 1_
- $a Partlová, Simona $u Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic; Sotio, Prague, Czech Republic. $7 _AN085265
- 700 1_
- $a Špíšek, Radek, $u Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic; Sotio, Prague, Czech Republic. $d 1975- $7 nlk20030145288
- 700 1_
- $a Fučíková, Jitka, $u Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic; Sotio, Prague, Czech Republic. Electronic address: jitka.fucikova@fnmotol.cz. $d 1983- $7 xx0116819
- 773 0_
- $w MED00002200 $t Immunology letters $x 1879-0542 $g Roč. 160, č. 1 (2014), s. 39-49
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24726860 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20191015112908 $b ABA008
- 999 __
- $a ok $b bmc $g 1071984 $s 897281
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 160 $c 1 $d 39-49 $i 1879-0542 $m Immunology letters $n Immunol Lett $x MED00002200
- GRA __
- $a NT12402 $p MZ0
- LZP __
- $a Pubmed-20150420